“GlaxoSmithKline (GSK) will pay 23andMe $20 million to extend its five-year contract to mine the company’s consumer DNA data for another year.
The drugmaker is searching for hints about genes that might be at the root of disease. 23andMe will get royalties on any drugs developed.”